Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | IDH2 R172X |
Gene Variant Detail | |
Relevant Treatment Approaches | IDH Inhibitor (Pan) IDH2 Inhibitor |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03839771 | Phase III | Ivosidenib Enasidenib | A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML) | Active, not recruiting | SWE | NOR | NLD | LUX | LTU | IRL | FRA | FIN | EST | ESP | DEU | CHE | BEL | AUT | AUS | 0 |
NCT04522895 | Phase II | Enasidenib | IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT | Completed | DEU | 0 |
NCT03383575 | Phase II | Azacitidine + Enasidenib Enasidenib | Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT06176989 | Phase II | Enasidenib | Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors | Recruiting | USA | 0 |
NCT04603001 | Phase I | LY3410738 | Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations | Active, not recruiting | USA | ISR | FRA | FIN | ESP | DEU | CAN | BEL | AUS | 3 |
NCT05441514 | Phase I | Cobimetinib + Enasidenib | Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT03515512 | Phase I | Enasidenib | IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation | Completed | USA | 0 |
NCT04521686 | Phase I | LY3410738 | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | Active, not recruiting | USA | FRA | ESP | AUS | 5 |
NCT03528642 | Phase I | Radiotherapy + Telaglenastat + Temozolomide | Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma | Active, not recruiting | USA | 0 |
NCT04092179 | Phase Ib/II | Enasidenib + Venetoclax | Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers | Terminated | CAN | 0 |
NCT03914742 | Phase Ib/II | Pamiparib + Temozolomide | BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations | Completed | USA | 0 |